Research programme: small molecule therapeutics - Alion Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Alion Pharmaceuticals

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alion Pharmaceuticals
  • Class Antidementias; Small molecules
  • Mechanism of Action Ion channel modulators; Protein interaction domain and motif modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 02 Apr 2018 Research programme: small molecule therapeutics - Alion Pharmaceuticals is available for licensing as of 02 Apr 2018.
  • 02 Apr 2018 Early research in Alzheimer's disease in USA (unspecified route) (Alion Pharmaceuticals pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top